French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update - 01/11/23

Endorsed by the Investigation Network On Venous Thrombo-Embolism (INNOVTE) and the French Speaking Society of Respiratory Diseases (SPLF)

Doi : 10.1016/j.resmer.2023.101056

Isabelle Mahé ^a,^⁎ , Guy Meyer ^b, Philippe Girard ^c, Laurent Bertoletti ^d, Silvy Laporte ^e, Francis Couturaud ^f, Patrick Mismetti ^d, Olivier Sanchez ^g
for the
Best Practice Guidelines for VTE Management Working Group
^a Paris Cité University; Internal Medicine Department - Louis Mourier Hospital, Assistance Publique des Hôpitaux de Paris, Colombes; Inserm UMR_S1140, Paris; F-CRIN INNOVTE, St-Etienne
^b Paris Cité University; Pulmonology and Intensive Care Department, Georges Pompidou European Hospital, Assistance Publique des Hôpitaux de Paris; INSERM UMRS 970; INSERM CIC 1418, Paris; F-CRIN INNOVTE, St-Etienne
^c Curie-Montsouris Thorax Institute, Montsouris Mutualist Institute, Paris; F-CRIN INNOVTE, St-Etienne
^d Vascular and Therapeutic Medicine Department, St-Etienne University Hospital; INSERM UMR1059, Vascular Dysfunction and Hemostasis Team, Jean-Monnet University, Saint-Etienne; INSERM, CIC-1408, Saint-Etienne; F-CRIN INNOVTE, Saint-Etienne, France
^e SAINBOIS U1059 DVH team, Jean Monnet University, Lyon University, INSERM; Clinical Research, Innovation, Pharmacology Unit, Saint-Etienne University Hospital, Hôpital Nord; Saint-Etienne; F-CRIN INNOVTE, St-Etienne
^f Internal Medicine and Pulmonology Department, EA3878-GETBO, CIC_INSERM1412, Western Brittany University, Brest University Hospital, F-CRIN INNOVTE, St-Etienne
^g Paris Cité University; Pulmonology and Intensive Care Department, Georges Pompidou European Hospital, Assistance Publique des Hôpitaux de Paris; INSERM UMRS 1140, Paris; F-CRIN INNOVTE, St-Etienne

^⁎Corresponding author, Isabelle Mahé, Internal Medicine department, Louis Mourier Hospital, Assistance Publique Hôpitaux de Paris, Pars Cité University France, Unité Inserm UMR_S1140 Innovation Thérapeutique en Hémostase, Paris, France, INNOVTE-FCRIN, 42055 Saint-Etienne Cedex 2, France, 178 rue des Renouillers 92700 Colombes, France, Tel 00 33 1 47 60 64 90, Fax 00 33 1 47 60 64 91Internal Medicine department, Louis Mourier Hospital, Assistance Publique Hôpitaux de ParisPars Cité University FranceUnité Inserm UMR_S1140 Innovation Thérapeutique en Hémostase, Paris, France, INNOVTE-FCRIN42055 Saint-Etienne Cedex 2, France, 178 rue des RenouillersColombes92700France

Abstract

Background

In recent years, knowledge about cancer associated thrombosis has evolved considerably.

Methods

Practical guidelines were drafted on the initiative of the INNOVTE FCRIN Network, led by the French Speaking Society of Respiratory Diseases (SPLF), by a coordinating group, a writing group, and a review group, with the involvement of different scientific societies practicing in various settings. The method followed the "Clinical Practice Guidelines" process of the French National Authority for Health (HAS).

Results

After a literature review, guidelines were formulated, improved, and then validated by the working groups. These guidelines addressed multiple aspects of the disease and management from the data of available clinical trials and observational studies : epidemiology, initial treatment, treatment duration, extended treatment, recurrent thrombosis, central venous catheter thrombosis, incidental thrombosis, treatment in case of thrombocytopenia.

Conclusion

These evidence-based guidelines are intended to guide the practical management of patients with cancer associated thrombosis

Le texte complet de cet article est disponible en PDF.

Keywords : cancer, thrombosis, treatment, guidelines

Plan

To which patients should these guidelines be applied?

Type of treatment for the first six months

Low-molecular-weight heparin or antivitamin K?

Benefits of direct oral anticoagulants (DOAs)

Treatment duration

Type of treatment beyond 6 months

Treatment of venous thromboembolic recurrence under anticoagulant treatment

Treatment of central venous catheter-associated thrombosis

Treatment of incidental pulmonary embolism

What to do in case of thrombocytopenia on anticoagulant treatment

Export

Vol 84

Article 101056- novembre 2023 Retour au numéro

Article précédent

Long-term survival comparison between the first and second waves among 265 critical COVID-19 patients admitted to the ICU: A retrospective cohort study
Nour-El-Imane Taghboulit, Claire Andrejak, Yazine Mahjoub, Bénédicte Toublanc, Isabelle Mayeux, Julia Delomez, Marie Mercier, Pauline Leriche, Julien Maizel, Hervé Dupont, Vincent Jounieaux, Damien Basille

| Article suivant

Long-term effect of tocilizumab on mortality, readmissions, persistent symptoms and lung function in SARS-CoV-2 patients 1 year after hospital discharge: A matched cohort study
Ignacio Cardona-Pascual, Mercedes Pallero, David Berlana, Ana Villar, Jose Bruno Montoro-Ronsano, Cristina Berastegui

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update - 01/11/23

Endorsed by the Investigation Network On Venous Thrombo-Embolism (INNOVTE) and the French Speaking Society of Respiratory Diseases (SPLF)

Abstract

Background

Methods

Results

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL